Bulletin
Investor Alert

GT Biopharma Inc.

NAS: GTBP

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
GT Biopharma Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 20, 2023, 4:07 p.m.

GTBP
/zigman2/quotes/200365724/composite

$

0.49

Change

-0.06 -10.47%

Volume

Volume 87

Quotes are delayed by 20 min

/zigman2/quotes/200365724/composite

Today's close

$ 0.53

$ 0.55

Change

+0.02 +3.24%

Day low

Day high

$0.50

$0.61

Open

52 week low

52 week high

$0.47

$3.29

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for GT Biopharma Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue -----
Cost of Goods Sold (COGS) incl. D&A 2,0007,0004,000--
COGS excluding D&A -----
Depreciation & Amortization Expense 2,0007,0004,000--
Depreciation 2,0007,0004,000--
Amortization of Intangibles -----
Gross Income (2,000)(7,000)(4,000)--
20172018201920202021 5-year trend
SG&A Expense 135.57M21.55M11.45M6.76M57.52M
Research & Development 1.07M9.07M1.67M485,0009.59M
Other SG&A 134.5M12.48M9.79M6.28M-
Other Operating Expense ----242,760
Unusual Expense -228.52M4.6M17.98M(182,000)
EBIT after Unusual Expense -(250.07M)(16.06M)(24.75M)(57.58M)
Non Operating Income/Expense --(20.46M)(230,000)-
Non-Operating Interest Income ----38,000
Equity in Affiliates (Pretax) -----
Interest Expense 8.6M9.12M2.13M3.32M718,000
Gross Interest Expense 8.6M9.12M2.13M3.32M718,000
Interest Capitalized -----
Pretax Income (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Minority Interest Expense -----
Net Income (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Preferred Dividends -----
Net Income Available to Common (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
EPS (Basic) (146.16)(87.70)(11.42)(6.45)(2.06)
Basic Shares Outstanding 986,4122.96M3.38M4.39M28.16M
EPS (Diluted) (146.16)(87.70)(11.42)(6.45)(2.06)
Diluted Shares Outstanding 986,4122.96M3.38M4.39M28.16M
EBITDA (135.57M)(21.55M)(11.45M)(6.76M)(57.76M)
Copyright 2023 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.